Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 5:2019:7135437.
doi: 10.1155/2019/7135437. eCollection 2019.

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma

Caroline Y K Fong  1 , Emma Burke  1 , David Cunningham  1 , Naureen Starling  1
Affiliations
Review

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma

Caroline Y K Fong et al. Gastroenterol Res Pract. .

Abstract

Despite intensive research efforts, pancreatic ductal adenocarcinoma is still regarded as an aggressive and life-limiting malignancy. Combination chemotherapy regimens that underpin the current treatment approach in the advanced setting have led to incremental survival gains in recent years but have failed to confer patients with a median overall survival that exceeds 12 months from diagnosis. Research has since focussed on understanding the role and interplay between various components of the desmoplastic stroma and tumour microenvironment, in addition to developing targeted therapies based on molecular features to improve the prognosis associated with this malignancy. This review will summarise the available systemic treatment options and discuss potential methods to refine the resolution of patient selection to enhance responses to currently available therapies. Furthermore, it will explore newer approaches anticipated to come to the fore of future clinical practice, such as agents targeting the DNA damage response and tumour microenvironment as well as immunotherapy-based combinations.

PubMed Disclaimer

Conflict of interest statement

Caroline Fong and Emma Burke have no conflicting interests to declare, commercial, intellectual, or otherwise.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Neoptolemos J. P., Palmer D. H., Ghaneh P., et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet. 2017;389(10073):1011–1024. doi: 10.1016/S0140-6736(16)32409-6. - DOI - PubMed
    1. Uesaka K., Boku N., Fukutomi A., et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) The Lancet. 2016;388(10041):248–257. doi: 10.1016/S0140-6736(16)30583-9. - DOI - PubMed
    1. Conroy T., Hammel P., Hebbar M., et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. The New England Journal of Medicine. 2018;379(25):2395–2406. doi: 10.1056/NEJMoa1809775. - DOI - PubMed
    1. Pancreatic cancer survival statistics | Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/s....

LinkOut - more resources